PTN — Palatin Technologies Share News
0.000.00%
Last trade - 00:00- $9.10m
- $1.61m
- $13.19m
Brief: Palatin Announces Direct-To-Consumer Telehealth Partnership With Upscripthealth For Vyleesi
Palatin Technologies rises on higher Q4 prelim product revenue
Palatin Technologies falls on bigger-than-expected Q3 loss
Brief: Palatin Reports Third Quarter Fiscal Year 2023 Financial Results And Provides Corporate Update
Brief: Palatin Technologies Says Melody-1 Phase 3 Clinical Study Continuing Patient Enrollment
Palatin Technologies rises on higher prelim product revenue for Vyleesi
Brief: Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results
Brief: Pre-Clinical Data Of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects In Diabetic Retinopathy And Uveitis Published In The International Journal Of Molecular Sciences
Brief: Palatin Issued Patent On Vyleesi For Hypoactive Sexual Desire Disorder In Patients With Controlled Hypertension
Brief: Palatin Reports Second Quarter Fiscal Year 2023 Financial Results
Brief: Palatin Initiates Enrollment In The Phase 2 Bremelanotide Breakout Study In Patients With Diabetic Kidney Disease
Brief: Palatin Receives $4.7 Million Of Non-Dilutive Funding
Brief: Palatin Announces Preliminary Q2 Fiscal 2023 Vyleesi Product Sales Results
Brief: Palatin Technologies Says First Patient Enrolls In Phase 2 Study Of PL8177 For Ulcerative Colitis
Brief: Palatin Announces Publication Of Vyleesi (Bremelanotide) FMRI Study In Women With Hypoactive Sexual Desire Disorder
Brief: Palatin Announces Preliminary Q1 2023 Vyleesi® Product Sales Results
Brief: Palatin Technologies Reports Qtrly Loss Per Share $1.34
U.S. RESEARCH ROUNDUP-New Jersey Resources, Spire, Waldencast
Brief: Palatin Technologies announces initiation of patient recruitment for Phase 2 Clinical Study Evaluating Oral Pl8177 for treatment of ulcerative colitis